Ionis Pharmaceuticals (IONS) Liabilities and Shareholders Equity (2009 - 2026)

Ionis Pharmaceuticals' Liabilities and Shareholders Equity history runs 18 years deep, the most recent figure standing at $3.4 billion for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 22.65% year-over-year to $3.4 billion in Q1 2026; TTM through Mar 2026 was $13.0 billion, a 12.11% increase from a year earlier, with the FY2025 full-year figure at $3.5 billion, up 17.32% from the prior year.
• Liabilities and Shareholders Equity eased to $3.4 billion in Q1 2026 per IONS's latest filing, from $3.5 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $3.5 billion in Q4 2025 and bottomed at $2.4 billion in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $2.9 billion (2023), against an average of $2.9 billion.
• Across the five-year window, Liabilities and Shareholders Equity decreased 9.42% in 2024 and grew 22.65% in 2026, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $2.5 billion in 2022, then gained by 18.0% to $3.0 billion in 2023, then climbed by 0.45% to $3.0 billion in 2024, then rose by 17.32% to $3.5 billion in 2025, then retreated by 2.1% to $3.4 billion in 2026.
• Per Business Quant, the three latest IONS Liabilities and Shareholders Equity figures stand at $3.4 billion (Q1 2026), $3.5 billion (Q4 2025), and $3.0 billion (Q3 2025).